Hualan Vac announced on the evening of January 16 that it expects to achieve a net profit attributable to shareholders of the listed company of 200 million to 250 million yuan in 2024, a year-on-year decrease of 76.74% to 70.93%. In June 2024, the company adjusted the prices of its quadrivalent influenza vaccine products, with the prices of major products reduced by more than 40%. In addition, in 2024, the company's business development and profitability were significantly impacted by multiple factors, including changes in public vaccination rates, a decline in vaccine market demand, and reduced sales, leading to a significant decline in the company's performance for the year